Approval to Manufacture and Market High-Purity EPA Product “Mochida”
Mochida Pharmaceutical Sales Co., Ltd. received approval on August 15, 2025, to manufacture and market 300 mg, 600 mg, and 900 mg strengths of the high-purity EPA product “Mochida.” These are authorized generics with the same active ingredient and manufacturing process as the Epadel S series manufactured and marketed by Mochida Pharmaceutical. Following approval, Mochida Pharmaceutical Sales will sell the products in partnership with Mochida Pharmaceutical.